New hope: immunotherapy tested as alternative to hormone therapy for prostate cancer
NCT ID NCT04019964
Summary
This study tested whether the immunotherapy drug nivolumab could control prostate cancer recurrence without using hormone-blocking treatments. It involved 8 men whose prostate cancer returned after initial treatment and who had specific genetic markers in their tumors. Researchers wanted to see if this drug could lower PSA levels and delay cancer spread while avoiding the side effects of hormone therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.